ASLAN Pharmaceuticals Limited
83 Clemenceau Avenue #12-03 UE Square
Singapore 239920
March 31, 2021
VIA EDGAR
U.S. Securities and Exchange Commission
Office of Healthcare and Insurance
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn: Mr. Chris Edwards
| Re: | ASLAN Pharmaceuticals Limited |
Registration Statement on Form F-3
File No. 333-254768
Acceleration Request
| Requested Date: | Wednesday, March 31, 2021 |
| Requested Time: | 4:00 P.M. Eastern Time |
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the “Registrant”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on Form F-3 to become effective on March 31, 2021, at 4:00 P.M. Eastern Time, or as soon thereafter as is practicable, or at such later time as its counsel may orally request via telephone call to the staff. The Registrant hereby authorizes each of J. Patrick Loofbourrow and Carlos Ramirez of Cooley LLP, counsel to the Registrant, to make such request on its behalf.
Once the Registration Statement has been declared effective, please orally confirm that event with Carlos Ramirez of Cooley LLP at (858) 550-6157, or in his absence, J. Patrick Loofbourrow of Cooley LLP at (619) 840-4824. Thank you for your assistance with this matter.
Sincerely,
ASLAN Pharmaceuticals Limited | ||
| By: | /s/ Carl Firth, Ph.D. | |
| Carl Firth, Ph.D. | ||
| Chief Executive Officer | ||
| cc: | Kiran Asarpota, ASLAN Pharmaceuticals Limited J. Patrick Loofbourrow, Cooley LLP Carlos Ramirez, Cooley LLP |
